



**William C. Rives, CFA**  
Portfolio Manager  
(industry since 2013)

#### Objective

The fund seeks long-term capital appreciation.

#### Type

Active, fully transparent

Putnam BioRevolution ETF is a traditional ETF with a transparent portfolio. The fund tells public investors and traders the securities it holds each day. This characteristic makes it different from semi-transparent ETFs that do not disclose the assets they hold each day.

<b>Ticker</b>	<b>CUSIP</b>
SYNB	746729805

#### Primary exchange

NYSE

#### Fund distributor

Foreside Fund Services, LLC

#### Inception

September 29, 2022

#### Management fee

0.70%

#### Benchmark

S&P 500 Index

# Putnam BioRevolution™ ETF (SYNB)

Investing in companies that are leveraging innovation within biology

#### Pursues transformative growth across sectors

The economic impact of the biology revolution is spreading beyond health care, with potential to transform multiple sectors and drive investment opportunities.

#### Collaborative research process

A benchmark-agnostic approach leverages unique, integrated insights of Putnam sector analysts and the Sustainable Equity team.

#### Concentrated portfolio

The manager seeks outperformance by investing in 30–50 high-conviction stocks selected through disciplined portfolio construction and risk management.

#### Pursuing growth from the biorevolution

A convergence of technological developments in life sciences has unleashed the ability to design and engineer biology-sourced products, ingredients, and materials on an industrial scale. We believe advances in areas such as DNA sequencing, gene editing, and biomanufacturing will have transformative impact for multiple industries, across a wide range of sectors, in coming decades. Putnam BioRevolution ETF seeks to harness for investors the benefits from this wave of innovation.

#### An active investment process

The ETF's investable universe is diversified across four primary sectors — health care, materials, consumer staples, and consumer discretionary — and represents more than 300 companies of all market cap sizes. Our investment process will focus on how the biorevolution can be additive to earnings and will combine three key types of businesses:



**Technology-enabling companies** that provide materials and knowledge to enable biological production and are poised to achieve accelerated revenue growth



**Disruptive bio or synbio companies** that apply biology as a fundamental element in their business models, and are likely to create entirely new markets



**Leading incumbents/early adopters** in established industries that are positioned to adapt over time and gain competitive advantages

#### Why ETFs?

- **Cost competitive**  
ETFs may reduce costs to investors, with a simplified fee structure compared to alternatives.
- **Tax efficient**  
The structure of ETFs can reduce the impact of capital gains distributions relative to other investment vehicles.
- **Intraday liquidity**  
ETFs trade at any time of day, offering convenience and price clarity when buying and selling.

#### Why active?

- **Potential for outperformance**  
Active strategies aim to outperform passive indexes through investment research and portfolio positioning.
- **Active risk management**  
Proactive analysis helps to identify better risk-reward potential than an index offers and seeks to reduce unintended risks.
- **Professional oversight**  
Experienced portfolio managers balance risk and return while delivering the ETF's structural benefits.

**Not FDIC insured  
May lose value  
No bank guarantee**

### A portfolio manager with unique experience seeing the impact of the biorevolution

William C. Rives, CFA, a Portfolio Manager and Analyst at Putnam, will manage the ETF. Will is in a vital position for understanding the advance of the biology revolution: He researches companies in the medical technology, life sciences, and utility industries, using fundamental analysis and developing insights on their material sustainability issues. Will has served as a Portfolio Manager of Putnam Research Fund since 2019 and has worked in the investment industry since he joined Putnam in 2013.



**William C. Rives, CFA**  
Portfolio Manager

The S&P 500® Index is an unmanaged index of common stock performance. You cannot invest directly in an index.

Shares of any ETF are bought and sold at market price (not NAV), may trade at a discount or premium to NAV, and are not individually redeemed from the fund. Brokerage commissions will reduce returns. Key risks for each fund are below.

**Consider these risks before investing:** Biology revolution companies face intense competition and potentially rapid product obsolescence. Biology revolution companies may be adversely affected by the loss or impairment of intellectual property rights and other proprietary information or changes in government regulations. The potential for an increased amount of required disclosure or lack of access to proprietary scientific information could negatively impact the performance of these companies.

Investments in small and/or midsize companies increase the risk of greater price fluctuations. Growth stocks may be more susceptible to earnings disappointments, and value stocks may fail to rebound. The value of investments in the fund's portfolio may fall or fail to rise over extended periods of time for a variety of reasons, including general economic, political, or financial market conditions; investor sentiment and market perceptions; government actions; geopolitical events or changes; and factors related to a specific issuer, geography, industry, or sector. These and other factors may lead to increased volatility and reduced liquidity in the fund's portfolio holdings.

As a non-diversified fund, the fund invests in fewer issuers and is more vulnerable than a more broadly diversified fund to fluctuations in the values of the securities it holds. Our investment techniques, analyses, and judgments may not produce the outcome we intend. The investments we select for the fund may not perform as well as other securities that we do not select for the fund. We, or the fund's other service providers, may experience disruptions or operating errors that could have a negative effect on the fund. You can lose money by investing in the fund.

**You should consider the fund's investment objectives, risks, charges, and expenses carefully before you invest. This and other important information is contained in the fund's prospectus available on Putnam.com or by calling 1-833-228-5577. Please read carefully before you invest.**

Putnam ETFs are distributed by Foreside Fund Services, LLC. Foreside is not affiliated with Putnam Investments.

**Putnam Investments | 100 Federal Street | Boston, MA 02110 | 1-833-228-5577 | putnam.com**